CollPlant Biotechnologies Reports Q4 GAAP Loss of $0.87 and Revenue Growth of 116% Year-over-Year
CollPlant Biotechnologies (CLGN) reported a fourth-quarter loss per share under GAAP accounting of -$0.87, with revenue reaching $11.43 million—a significant increase of 116.1% year-over-year. The company reaffirmed its guidance for FY 2026, projecting revenue growth between 50% and 100% compared to the previous fiscal year. The strong revenue performance reflects CollPlant's strategic initiatives in biotechnology innovation and market expansion. Additionally, the firm announced plans related to an acquisition of LightSolver, signaling its entry into high-performance photonic computing—a move expected to diversify its technological portfolio and open new growth avenues. Despite reporting a loss for the quarter, CollPlant’s revenue surge and forward-looking guidance indicate continued confidence in long-term business momentum.
Tickers: $CLGN
Topics: Acquisition Earnings Photonic Computing